1-(1-哌嗪基)-1-丁酮 | 18903-04-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(1-哌嗪基)-1-丁酮
• 英文名称: 1-butyrylpiperazine
• 英文别名: 1-(Piperazin-1-yl)butan-1-one；1-piperazin-1-ylbutan-1-one
• CAS: 18903-04-3
• 化学式: C₈H₁₆N₂O
• mdl: MFCD09811502
• 分子量: 156.228
• InChiKey: OGQQJMSDOICEAR-UHFFFAOYSA-N

物化性质

• 沸点：
  286.5±33.0 °C(Predicted)
• 密度：
  0.989±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P270,P271,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P403+P233,P405,P501
• 危险品运输编号：
  2735
• 危险性描述：
  H302,H335,H314
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  benzenediazonium tetrafluoroborate 、 1-(1-哌嗪基)-1-丁酮 在 吡啶 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 以85%的产率得到4-phenylazo-1-butyrylpiperazine
  参考文献：
  名称：

  Application of triazenes for protection of secondary amines

  摘要：

  Use of the phenyldiazenyl group, which serves as a protecting group for secondary amines is described in detail. The triazene protected amine is compatible with oxidative and reductive conditions as well as with strong bases (LDA, tert-butyllithium) and alkylating reagents. The amine is regenerated by action of trifluoroacetic acid and a suitable reducing agent (EtOH or NaH2PO2). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(01)00495-1
• 作为产物：
  描述：

  4-benzyl-1-butyrylpiperazine 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 生成 1-(1-哌嗪基)-1-丁酮
  参考文献：
  名称：

  New antiproliferative benzoindolinothiazepines derivatives

  摘要：

  New benzoindolinothiazepines containing a piperazine moiety are described as potent antiproliferative agents against PC3 human prostatic cell lines. This activity could be explained by an accumulation of cells in G1 phase. (C) 2004 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2004.10.008

文献信息

• [EN] WNT PATHWAY ANTAGONISTS<br/>[FR] ANTAGONISTES DE LA VOIE WNT
  申请人：SIENA BIOTECH SPA

  公开号：WO2011042145A1

  公开（公告）日：2011-04-14

  The present invention relates to known and novel compounds of formula (I) as herein described and pharmaceutical compositions thereof. The compounds of formula (I) have inhibitory effect on the Wnt pathway and are therefore useful in the preparation of a medicament, in particular for the treatment of cancer.

  本发明涉及如下所述的已知和新颖的化合物（I）的公式及其药物组成。公式（I）的化合物对Wnt途径具有抑制作用，因此在制备药物方面特别适用于治疗癌症。
• THIAZOLE COMPOUND AND USE THEREOF
  申请人：Otsuka Pharmaceutical Company, Limited

  公开号：EP1748044A1

  公开（公告）日：2007-01-31

  An object of the present invention is to provide a novel thiazole compound with specific inhibitory activity against phosphodiesterase 4. The present invention provides a compound represented by Formula (1), an optical isomer thereof, or a salt thereof: wherein R1 is a di-C1-6 alkoxyphenyl group; R2 is any one of the following groups (a) to (t): (a) a phenyl group; (b) a naphthyl group; (c) a pyridyl group; (d) a furyl group; (e) a thienyl group; (f) an isoxazolyl group; (g) a thiazolyl group; (h) a pyrrolyl group; (i) an imidazolyl group; (j) a tetrazolyl group; (k) a pyrazinyl group; (1) a thienothienyl group; (m) a benzothienyl group; (n) an indolyl group; (o) a benzimidazolyl group; (p) an indazolyl group; (q) a quinolyl group; (r) a 1,2,3,4-tetrahydroquinolyl group; (s) a quinoxalinyl group; and (t) a 1,3-benzodioxolyl group; and A is any one of the following groups (i) to (vi): (i) -CO-B- wherein B is a C1-6 alkylene group; (ii) -CO-Ba wherein Ba is a C2-6 alkenylene group; (iii) -CH(OH)-B-; (iv) -COCH(COOR3)-Bb- wherein R3 is a C1-6 alkyl group and Bb is a C1-6 alkylene group; and (v) -Bc- wherein Bc is a C2-6 alkylene group.

  本发明的目的是提供一种对磷酸二酯酶4具有特异抑制活性的新型噻唑化合物。本发明提供一种由式（1）表示的化合物，其光学异构体或盐：其中R1是二C1-6烷氧基苯基基团；R2是以下分组之一（a）至（t）中的任意一种：（a）苯基；（b）萘基；（c）吡啶基；（d）呋喃基；（e）噻吩基；（f）异氧唑基；（g）噻唑基；（h）吡咯基；（i）咪唑基；（j）四唑基；（k）吡嗪基；（l）噻吩噻吩基；（m）苯并噻吩基；（n）吲哚基；（o）苯并咪唑基；（p）吲哚基；（q）喹啉基；（r）1,2,3,4-四氢喹啉基；（s）喹啉基；和（t）1,3-苯并二氧杂环戊基；以及A是以下分组之一（i）至（vi）中的任意一种：（i）-CO-B-，其中B是C1-6烷基基团；（ii）-CO-Ba，其中Ba是C2-6烯基基团；（iii）-CH(OH)-B-；（iv）-COCH(COOR3)-Bb-，其中R3是C1-6烷基基团，Bb是C1-6烷基基团；和（v）-Bc-，其中Bc是C2-6烷基基团。
• Synthesis, antitumor evaluation and molecular docking studies of [1,2,4]triazolo[4,3- b ][1,2,4,5]tetrazine derivatives
  作者：Feng Xu、Zhen-zhen Yang、Jun-rong Jiang、Wan-gui Pan、Xiao-le Yang、Jian-yong Wu、Yan Zhu、John Wang、Qi-Yang Shou、Han-gui Wu

  DOI：10.1016/j.bmcl.2016.05.007

  日期：2016.7

  A series of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives have been synthesized and evaluated for their antitumor activities. These compounds exhibited potent antiproliferative activities against MCF-7, Bewo and HL-60 cells and c-Met kinase inhibitory activities. Three compounds were highly effective against MCF-7, Bewo and HL-60 cells with IC50 values in 1.09-2.24μM. Molecular docking was further

  合成了一系列[1,2,4]三唑并[4,3-b] [1,2,4,5]四嗪衍生物并评估了其抗肿瘤活性。这些化合物对MCF-7，Bewo和HL-60细胞显示出有效的抗增殖活性，并具有c-Met激酶抑制活性。三种化合物对MCF-7，Bewo和HL-60细胞高度有效，IC50值为1.09-2.24μM。进一步进行分子对接研究抑制剂-c-Met激酶的相互作用，结果表明化合物4j通过三个氢键有效地结合到c-Met激酶上。对化合物4j对ICR（Institute of Cancer Research，小鼠）的急性毒性和体内抗肿瘤活性进行了进一步研究，发现4j具有一定的毒性，但在体内具有良好的疗效。根据初步结果，
• DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS
  申请人：Matsuyama Hironori

  公开号：US20100004438A1

  公开（公告）日：2010-01-07

  An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X 1 represents a nitrogen atom or a group —CH═, R 1 represents a group -Z-R 6 , in which Z represents a group —CO—, a group —CH(OH)— or the like, R 6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R 2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R 3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的一个目的是提供一种在抗肿瘤活性方面大大改进且安全性优异的药物。根据本发明，提供了一种包含以下一般式（1）所表示的化合物或其盐作为活性成分的药物：[式1]其中X1代表氮原子或基团—CH═，R1代表一个基团-Z-R6，其中Z代表基团—CO—，基团—CH(OH)—或类似的基团，R6代表一个含有1至4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团，R2代表氢原子或卤原子，Y代表基团—O—，基团—CO—，基团—CH(OH)—或低碳烷基基团，A代表[式2]其中R3代表氢原子、低碳氧基基团或类似基团，p代表1或2，R4代表咪唑基低碳基团或类似基团。
• [EN] BIARYL INHIBITORS OF THE SODIUM CHANNEL<br/>[FR] INHIBITEURS BIARYLE DU CANAL SODIQUE
  申请人：ZALICUS PHARMACEUTICALS LTD

  公开号：WO2013131018A1

  公开（公告）日：2013-09-06

  The invention relates to compounds useful in treating conditions associated with voltage- gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns biaryl derivatives (e.g., compounds according to any of Formulas (I)-(XII) or Compounds (l)-(372) of Table 1) that are that are useful in treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotropic lateral sclerosis, glaucoma, ischaemia, spasticity disorders, obsessive compulsive disorder, restless leg syndrome and Tourette syndrome.

  该发明涉及与电压门控离子通道功能相关的化合物，特别是与钠通道活性相关的病症。更具体地说，该发明涉及联萘衍生物（例如，根据表1的任一公式（I）-（XII）或化合物（l）-（372）的化合物），这些化合物可用于治疗癫痫、癌症、疼痛、偏头痛、帕金森病、情绪障碍、精神分裂症、精神病、耳鸣、肌萎缩性侧索硬化、青光眼、缺血、痉挛性障碍、强迫症、不安腿综合征和抽动症等病症的治疗。